The future of inpatient diabetes management: Glucose as the sixth vital sign

Expert Review of Endocrinology and Metabolism

Volumn 8, Issue 2, 2013, Pages 195-205

  Rendell, Marc ^a,b   Saiprasad, Saraswathi ^c   Trepp Carrasco, Alejandro G ^c   Drincic, Andjela ^d  

^a Creighton Diabetes Center   (United States)

^b Rose Salter Medical Research Foundation   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

continuous glucose monitors; diabetes; hospital systems; hyperglycemia; insulin pumps

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; SHORT ACTING INSULIN;

BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG DOSE TITRATION; DRUG HALF LIFE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN PUMP; INSULIN RESISTANCE; INSULIN TREATMENT; LENGTH OF STAY; MORTALITY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; WOUND INFECTION;

EID: 84874618885     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.13.1     Document Type: Review

References (98)

1. Garber AJ, Moghissi ES, Bransome ED Jr et al. ; American College of Endocrinology Task Force on Inpatient Diabetes Metabolic Control. American College of Endocrinology position statement on inpatient diabetes and metabolic control. Endocr. Pract. 10 (Suppl. 2), 4 - 9 (2004).
2. Clement S, Braithwaite SS, Magee MF et al. ; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care 27 (2), 553 - 591 (2004).
3. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care 31 (3), 596 - 615 (2008).
4. Evans NR, Dhatariya KK. Assessing the relationship between admission glucose levels, subsequent length of hospital stay, readmission and mortality. Clin. Med. 12 (2), 137 - 139 (2012).
5. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359 (9324), 2140 - 2144 (2002).
6. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit. Care Med. 37 (12), 3001 - 3009 (2009).
7. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N. Engl. J. Med. 341 (25), 1906 - 1912 (1999).
8. Jämsen E, Nevalainen P, Kalliovalkama J, Moilanen T. Preoperative hyperglycemia predicts infected total knee replacement. Eur. J. Intern. Med. 21 (3), 196 - 201 (2010).
9. Park C, Hsu C, Neelakanta G et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after liver transplantation. Transplantation 87 (7), 1031 - 1036 (2009).
10. Guvener M, Pasaoglu I, Demircin M, Oc M. Perioperative hyperglycemia is a strong correlate of postoperative infection in Type II diabetic patients after coronary artery bypass grafting. Endocr. J. 49 (5), 531 - 537 (2002).
11. Vilar-Compte D, Alvarez de Iturbe I, Martín-Onraet A, Pérez-Amador M, Sánchez-Hernández C, Volkow P. Hyperglycemia as a risk factor for surgical site infections in patients undergoing mastectomy. Am. J. Infect. Control 36 (3), 192 - 198 (2008).
12. Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS Jr. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect. Control Hosp. Epidemiol. 22 (10), 607 - 612 (2001).
13. Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int. J. Cardiol. 79 (2-3), 207 - 214 (2001).
14. Lazzeri C, Valente S, Chiostri M, Picariello C, Gensini GF. In-hospital peak glycemia and prognosis in STEMI patients without earlier known diabetes. Eur. J. Cardiovasc. Prev. Rehabil. 17 (4), 419 - 423 (2010).
15. Angeli F, Verdecchia P, Karthikeyan G et al. New-onset hyperglycemia and acute coronary syndrome: a systematic overview and meta-analysis. Curr. Diabetes Rev. 6 (2), 102 - 110 (2010).
16. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 355 (9206), 773 - 778 (2000).
17. Hyvärinen M, Tuomilehto J, Mähönen M et al. ; DECODE Study Group. Hyperglycemia and incidence of ischemic and hemorrhagic stroke-comparison between fasting and 2-hour glucose criteria. Stroke 40 (5), 1633 - 1637 (2009).
18. Stead LG, Gilmore RM, Bellolio MF et al. Hyperglycemia as an independent predictor of worse outcome in non-diabetic patients presenting with acute ischemic stroke. Neurocrit. Care 10 (2), 181 - 186 (2009).
19. Alvarez-Sabín J, Molina CA, Ribó M et al. Impact of admission hyperglycemia on stroke outcome after thrombolysis: risk stratification in relation to time to reperfusion. Stroke. 35 (11), 2493 - 2498 (2004).
20. Moghissi ES, Korytkowski MT, DiNardo M et al. ; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 32 (6), 1119 - 1131 (2009).
21. Umpierrez GE, Hellman R, Korytkowski MT et al. ; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 97 (1), 16 - 38 (2012).
22. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314 (7093), 1512 - 1515 (1997).
23. Van den Berghe G, Wouters PJ, Bouillon R et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. Crit. Care Med. 31 (2), 359 - 366 (2003).
24. Furnary AP, Wu Y, Bookin SO. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland Diabetic Project. Endocr. Pract. 10 (Suppl. 2), 21 - 33 (2004).
25. Van den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. N. Engl. J. Med. 354 (5), 449 - 461 (2006).
26. Finfer S, Chittock DR, Su SY et al. ; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N. Engl. J. Med. 360 (13), 1283 - 1297 (2009).
27. Vriesendorp TM, DeVries JH, van Santen S et al. Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit. Care Med. 34 (11), 2714 - 2718 (2006).
28. Kosiborod M, Inzucchi SE, Goyal A et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 301 (15), 1556 - 1564 (2009).
29. Kagansky N, Levy S, Rimon E et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch. Intern. Med. 163 (15), 1825 - 1829 (2003).
30. Ismail-Beigi F, Craven T, Banerji MA et al. ; ACCORD trial group. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in Type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376 (9739), 419 - 430 (2010).
31. Gerstein HC, Miller ME, Genuth S et al. ; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 364 (9), 818 - 828 (2011).
32. Griesdale DE, de Souza RJ, van Dam RM et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 180 (8), 821 - 827 (2009).
33. Van den Berghe G, Schetz M, Vlasselaers D et al. Clinical review: intensive insulin therapy in critically ill patients: NICESUGAR or Leuven blood glucose target? J. Clin. Endocrinol. Metab. 94 (9), 3163 - 3170 (2009).
34. Pichardo-Lowden AR, Fan CY, Gabbay RA. Management of hyperglycemia in the non-intensive care patient: featuring subcutaneous insulin protocols. Endocr. Pract. 17 (2), 249 - 260 (2011).
35. Wexler DJ, Cagliero E. Inpatient diabetes management in non-ICU settings: evidence and strategies. Curr. Diabetes Rev. 3 (4), 239 - 243 (2007).
36. Wexler DJ. Inpatient diabetes management in general medical and surgical settings: evidence and update. Expert Rev. Pharmacoecon. Outcomes Res. 7 (5), 491 - 502 (2007).
37. Boucher JL, Swift CS, Franz MJ et al. Inpatient management of diabetes and hyperglycemia: implications for nutrition practice and the food and nutrition professional. J. Am. Diet. Assoc. 107 (1), 105 - 111 (2007).
38. Petersen KF, Shulman GI. Etiology of insulin resistance. Am. J. Med. 119 (5 Suppl. 1), S10 - S16 (2006).
39. Bray GA. Medical consequences of obesity. J. Clin. Endocrinol. Metab. 89 (6), 2583 - 2589 (2004).
40. James WP. The epidemiology of obesity: the size of the problem. J. Intern. Med. 263 (4), 336 - 352 (2008).
41. Gallagher EJ, Leroith D, Karnieli E. Insulin resistance in obesity as the underlying cause for the metabolic syndrome. Mt. Sinai J. Med. 77 (5), 511 - 523 (2010).
42. Boden G. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes. Obes. 18 (2), 139 - 143 (2011).
43. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J. Clin. Endocrinol. Metab. 54 (1), 131 - 138 (1982).
44. Lansang MC, Hustak LK. Glucocorticoidinduced diabetes and adrenal suppression: how to detect and manage them. Cleve. Clin. J. Med. 78 (11), 748 - 756 (2011).
45. Lee H, Koh SO, Park MS. Higher dextrose delivery via TPN related to the development of hyperglycemia in non-diabetic critically ill patients. Nutr. Res. Pract. 5 (5), 450 - 454 (2011).
46. Via MA, Mechanick JI. Inpatient enteral and parenteral [corrected] nutrition for patients with diabetes. Curr. Diab. Rep. 11 (2), 99 - 105 (2011).
47. Lin LY, Lin HC, Lee PC, Ma WY, Lin HD. Hyperglycemia correlates with outcomes in patients receiving total parenteral nutrition. Am. J. Med. Sci. 333 (5), 261 - 265 (2007).
48. Pasquel FJ, Spiegelman R, McCauley M et al. Hyperglycemia during total parenteral nutrition: an important marker of poor outcome and mortality in hospitalized patients. Diabetes Care 33 (4), 739 - 741 (2010).
49. Harlev A, Wiznitzer A. New insights on glucose pathophysiology in gestational diabetes and insulin resistance. Curr. Diab. Rep. 10 (3), 242 - 247 (2010).
50. Lain KY, Catalano PM. Metabolic changes in pregnancy. Clin. Obstet. Gynecol. 50 (4), 938 - 948 (2007).
51. Fagulha A, Carvalheiro M, Fagulha I et al. Insulin sensitivity and insulin secretion in lean and obese normal pregnant women. Ann. Ist. Super. Sanita 33 (3), 367 - 370 (1997).
52. García-Patterson A, Gich I, Amini SB, Catalano PM, de Leiva A, Corcoy R. Insulin requirements throughout pregnancy in women with Type 1 diabetes mellitus: three changes of direction. Diabetologia 53 (3), 446 - 451 (2010).
53. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit. Care Clin. 17 (1), 107 - 124 (2001).
54. Lager I. The insulin-antagonistic effect of the counterregulatory hormones. J. Intern. Med. Suppl. 735, 41 - 47 (1991).
55. Bolli GB, Perriello G. Impact of activated glucose counterregulation on insulin requirements in insulin-dependent diabetes mellitus. Horm. Metab. Res. Suppl. 24, 87 - 96 (1990).
56. Smith U, Lager I. Insulin-antagonistic effects of counterregulatory hormones: clinical and mechanistic aspects. Diabetes. Metab. Rev. 5 (6), 511 - 525 (1989).
57. Rendell M. The role of sulphonylureas in the management of Type 2 diabetes mellitus. Drugs 64 (12), 1339 - 1358 (2004).
58. Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. Metab. Clin. Exp. 55 (9), 1263 - 1281 (2006).
59. Lipska KJ, Ross JS. Switching from rosiglitazone: thinking outside the class. JAMA 305 (8), 820 - 821 (2011).
60. Erdmann E, Charbonnel B, Wilcox RG et al. ; PROactive investigators. Pioglitazone use and heart failure in patients with Type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 30 (11), 2773 - 2778 (2007).
61. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and Type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370 (9593), 1129 - 1136 (2007).
62. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr. Opin. Clin. Nutr. Metab. Care 11 (4), 491 - 499 (2008).
63. Pfeifer MA, Halter JB, Porte D Jr. Insulin secretion in diabetes mellitus. Am. J. Med. 70 (3), 579 - 588 (1981).
64. Wolever TM, Bolognesi C. Prediction of glucose and insulin responses of normal subjects after consuming mixed meals varying in energy, protein, fat, carbohydrate and glycemic index. J. Nutr. 126 (11), 2807 - 2812 (1996).
65. Moghissi ES. Insulin strategies for managing inpatient and outpatient hyperglycemia and diabetes. Mt. Sinai J. Med. 75 (6), 558 - 566 (2008).
66. Goldberg PA, Siegel MD, Sherwin RS et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. Diabetes Care 27 (2), 461 - 467 (2004).
67. Rea RS, Donihi AC, Bobeck M et al. Implementing an intravenous insulin infusion protocol in the intensive care unit. Am. J. Health. Syst. Pharm. 64 (4), 385 - 395 (2007).
68. Nazer LH, Chow SL, Moghissi ES. Insulin infusion protocols for critically ill patients: a highlight of differences and similarities. Endocr. Pract. 13 (2), 137 - 146 (2007).
69. DeSantis AJ, Schmeltz LR, Schmidt K et al. Inpatient management of hyperglycemia: the Northwestern experience. Endocr. Pract. 12 (5), 491 - 505 (2006).
70. Kanji S, Singh A, Tierney M, Meggison H, McIntyre L, Hebert PC. Standardization of intravenous insulin therapy improves the efficiency and safety of blood glucose control in critically ill adults. Intensive Care Med. 30 (5), 804 - 810 (2004).
71. Hipszer B, Joseph J, Kam M. Pharmacokinetics of intravenous insulin delivery in humans with Type 1 diabetes. Diabetes Technol. Ther. 7 (1), 83 - 93 (2005).
72. Alish CJ, Garvey WT, Maki KC et al. A diabetes-specific enteral formula improves glycemic variability in patients with Type 2 diabetes. Diabetes Technol. Ther. 12 (6), 419 - 425 (2010).
73. Korytkowski MT, Salata RJ, Koerbel GL et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care 32 (4), 594 - 596 (2009).
74. Umpierrez GE. Basal versus sliding-scale regular insulin in hospitalized patients with hyperglycemia during enteral nutrition therapy. Diabetes Care 32 (4), 751 - 753 (2009).
75. Vogel CM, Kingsbury RJ, Baue AE. Intravenous hyperalimentation: a review of two and one-half years' experience. Arch. Surg. 105 (3), 414 - 419 (1972).
76. Piraino AJ, Firpo JJ, Powers DV. Prolonged hyperalimentation in catabolic chronic dialysis therapy patients. JPEN. J. Parenter. Enteral. Nutr. 5 (6), 463 - 477 (1981).
77. Reed MA, Pories WJ, Chapman W et al. Roux-en-Y gastric bypass corrects hyperinsulinemia implications for the remission of Type 2 diabetes. J. Clin. Endocrinol. Metab. 96 (8), 2525 - 2531 (2011).
78. Rossetti P, Pampanelli S, Fanelli C et al. Intensive replacement of basal insulin in patients with Type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 26 (5), 1490 - 1496 (2003).
79. Nau KC, Lorenzetti RC, Cucuzzella M, Devine T, Kline J. Glycemic control in hospitalized patients not in intensive care: beyond sliding-scale insulin. Am. Fam. Physician 81 (9), 1130 - 1135 (2010).
80. Franc S, Dardari D, Boucherie B et al. Real-life application and validation of flexible intensive insulin-therapy algorithms in Type 1 diabetes patients. Diabetes Metab. 35 (6), 463 - 468 (2009).
81. Cengiz E, Sherr JL, Weinzimer SA, Tamborlane WV. New-generation diabetes management: glucose sensor-augmented insulin pump therapy. Expert Rev. Med. Devices 8 (4), 449 - 458 (2011).
82. Oliver NS, Toumazou C, Cass AE, Johnston DG. Glucose sensors: a review of current and emerging technology. Diabet. Med. 26 (3), 197 - 210 (2009).
83. Girardin CM, Huot C, Gonthier M, Delvin E. Continuous glucose monitoring: a review of biochemical perspectives and clinical use in Type 1 diabetes. Clin. Biochem. 42 (3), 136 - 142 (2009).
84. Rebrin K, Sheppard NF Jr, Steil GM. Use of subcutaneous interstitial fluid glucose to estimate blood glucose: revisiting delay and sensor offset. J. Diabetes Sci. Technol. 4 (5), 1087 - 1098 (2010).
85. Tamborlane WV, Beck RW, Bode BW et al. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N. Engl. J. Med. 359 (14), 1464 - 1476 (2008).
86. Cohen O, Körner A, Chlup R et al. ; Central and Eastern Europe, Greece, and Israel Continuous Glucose Sensing Collaborative Study Group. Improved glycemic control through continuous glucose sensor-augmented insulin pump therapy: prospective results from a community and academic practice patient registry. J. Diabetes Sci. Technol. 3 (4), 804 - 811 (2009).
87. Hermanides J, Engström AE, Wentholt IM et al. Sensor-augmented insulin pump therapy to treat hyperglycemia at the coronary care unit: a randomized clinical pilot trial. Diabetes Technol. Ther. 12 (7), 537 - 542 (2010).
88. Leonhardi BJ, Boyle ME, Beer KA et al. Use of continuous subcutaneous insulin infusion (insulin pump) therapy in the hospital: a review of one institution's experience. J. Diabetes Sci. Technol. 2 (6), 948 - 962 (2008).
89. Nassar AA, Partlow BJ, Boyle ME, Castro JC, Bourgeois PB, Cook CB. Outpatientto-inpatient transition of insulin pump therapy: successes and continuing challenges. J. Diabetes Sci. Technol. 4 (4), 863 - 872 (2010).
90. Bailon RM, Partlow BJ, Miller-Cage V et al. Continuous subcutaneous insulin infusion (insulin pump) therapy can be safely used in the hospital in select patients. Endocr. Pract. 15 (1), 24 - 29 (2009).
91. Einis SB, Mednis GN, Rogers JE, Walton DA. Cultivating quality: a program to train inpatient pediatric nurses in insulin pump use. Am. J. Nurs. 111 (7), 51 - 55 (2011).
92. Continuous Glucose Monitoring: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 96 (10), 2968 - 2979 (2011).
93. Magee MF, Clement S. Subcutaneous insulin therapy in the hospital setting: issues, concerns, and implementation. Endocr. Pract. 10 (Suppl. 2), 81 - 88 (2004).
94. Maynard G, Wesorick DH, O'Malley C, Inzucchi SE ; Society of Hospital Medicine Glycemic Control Task Force. Subcutaneous insulin order sets and protocols: effective design and implementation strategies. J. Hosp. Med. 3 (Suppl. 5), 29 - 41 (2008).
95. Larsen J, Goldner W. Approach to the hospitalized patient with severe insulin resistance. J. Clin. Endocrinol. Metab. 96 (9), 2652 - 2662 (2011).
96. Cook CB, Seifert KM, Hull BP et al. Inpatient to outpatient transfer of diabetes care: planning for an effective hospital discharge. Endocr. Pract. 15 (3), 263 - 269 (2009).
97. Newton CA, Young S. Financial implications of glycemic control: results of an inpatient diabetes management program. Endocr. Pract. 12 (Suppl. 3), 43 - 48 (2006).
98. National Diabetes Information Clearing House. Fast facts on diabetes. http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#fasttes (Accessed 30 January 2012)